Guest Editor(s)

• Prof. Lucyna Kepka, MD, PhD

  Military Institute of Medicine, Warsaw, Poland.

  Website | E-mail

Special Issue Introduction

Radiotherapy is widely used for the treatment of brain metastases from lung cancer (both small and non-small cell). Survival after development of brain metastases is poor, however, with the advances in immunotherapy and molecular targeted therapies, some patients may achieve a long-term survival even with disseminated disease. For such patients, the neurotoxicity of whole brain radiotherapy (WBRT) is of particular concern and there is a need to use more focused forms of radiotherapy as radiosurgery, or hippocampal-sparing. In some patients, radiotherapy of brain may be avoided. Others benefit from radiotherapy in form of WBRT or radiosurgery or both. In this special issue, we aimed to present an available evidence as well as areas of research on radiotherapy of brain metastases from lung cancer.
Topics include but not limited to:
• Incorporation of molecular alterations of NSCLC in making treatment decisions of brain metastases
• WBRT as still valid option for brain metastases from lung cancer
• Avoidance of WBRT in brain metastases from lung cancer in patients available for neurosurgery or radiosurgery
• Avoidance of WBRT in brain metastases from lung cancer in patients who are not available for neurosurgery or radiosurgery

Keywords

Lung cancer, brain metastases, whole-brain radiotherapy, radiosurgery

Submission Deadline

31 Dec 2018

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jcmtjournal.com/pages/view/author_instructions
For Online Submission, please login at https://mc03.manuscriptcentral.com/jcmt
Submission Deadline: 31 Dec, 2018
Contacts: Ellian Huang, Assistant Editor, editor001@jcmtjournal.com